{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T13:40:49Z","timestamp":1772718049722,"version":"3.50.1"},"reference-count":21,"publisher":"Walter de Gruyter GmbH","issue":"7","funder":[{"DOI":"10.13039\/501100002301","name":"Eesti Teadusagentuur","doi-asserted-by":"publisher","award":["grants IUT34-12 and PRG1021"],"award-info":[{"award-number":["grants IUT34-12 and PRG1021"]}],"id":[{"id":"10.13039\/501100002301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["3.2.0701.12\u20130047"],"award-info":[{"award-number":["3.2.0701.12\u20130047"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Tartu, Institute of clinical medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpm-2022-0127_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To estimate the value of screening maternal serum soluble fms-like tyrosine kinase\/placental growth factor (sFlt-1\/PlGF) ratio in asymptomatic women during 3rd trimester to predict preeclampsia (PE) development.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2022-0127_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The investigated group comprised of 178 pregnant women. During this gestation, 24 cases had developed PE and 12 isolated gestational hypertension (GH); whereas 142 remained normotensive. Blood samples were collected between 180 and 259 gestational days (g.d.) when the participants were asymptomatic. Serums were analyzed using the BRAHMS sFlt-1 Kryptor\/BRAHMS PlGF plus Kryptor PE ratio test (Thermo Fisher Scientific, Henningdorf, Germany). High-risk pregnancies for the PE development were defined as sFlt-1\/PlGF&gt;38.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2022-0127_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The detection rate (DR) for manifestation of PE\u226430\u00a0days after sampling was 83.3% and overall DR during pregnancy 58.3%. Ten of 15 women having false positive prediction of PE suffered from GH, preterm birth and\/or delivery of a small-for-gestational-age-newborn. False positive rate was significantly higher at 239\u2013253 g.d. compared to sampling at 210\u2013224 g.d. and 225\u2013238 g.d. (21.9% vs. 7.8% and 5.3%; p &lt; 0.05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpm-2022-0127_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The sFlt-1\/PlGF test during 180\u2013259 g.d. detected approximately half of subsequent PE cases. An optimal time to use the test for screening purposes was estimated 225\u2013238 g.d. (DR 66.7%). False positive test results were more common to cases with other adverse pregnancy outcomes and samples drawn at higher gestational age.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpm-2022-0127","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T01:49:57Z","timestamp":1652406597000},"page":"939-946","source":"Crossref","is-referenced-by-count":6,"title":["Value of soluble fms-like tyrosine kinase-1\/placental growth factor test in third trimester of pregnancy for predicting preeclampsia in asymptomatic women"],"prefix":"10.1515","volume":"50","author":[{"given":"Ele","family":"Hanson","sequence":"first","affiliation":[{"name":"Women\u2019s Clinic of Tartu University Hospital , Tartu , Estonia"},{"name":"Department of Obstetrics and Gynaecology , University of Tartu , Tartu , Estonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-0716","authenticated-orcid":false,"given":"Kristiina","family":"Rull","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine and Translational Medicine, University of Tartu , Tartu , Estonia"},{"name":"Women\u2019s Clinic of Tartu University Hospital , Tartu , Estonia"},{"name":"Department of Obstetrics and Gynaecology , University of Tartu , Tartu , Estonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaspar","family":"Ratnik","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine and Translational Medicine, University of Tartu , Tartu , Estonia"},{"name":"SYNLAB Eesti O\u00dc , Tallinn , Estonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pille","family":"Vaas","sequence":"additional","affiliation":[{"name":"Women\u2019s Clinic of Tartu University Hospital , Tartu , Estonia"},{"name":"Department of Obstetrics and Gynaecology , University of Tartu , Tartu , Estonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pille","family":"Teesalu","sequence":"additional","affiliation":[{"name":"Women\u2019s Clinic of Tartu University Hospital , Tartu , Estonia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maris","family":"Laan","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine and Translational Medicine, University of Tartu , Tartu , Estonia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"2023040100081895961_j_jpm-2022-0127_ref_001","doi-asserted-by":"crossref","unstructured":"Tranquilli, AL, Dekker, G, Magee, L, Roberts, J, Sibai, BM, Steyn, W, et al.. The classification, diagnosis and management of the hypertensive disorders of pregnancy: a revised statement from the ISSHP. Pregnancy Hypertens 2014;4:97\u2013104. https:\/\/doi.org\/10.1016\/j.preghy.2014.02.001.","DOI":"10.1016\/j.preghy.2014.02.001"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_002","doi-asserted-by":"crossref","unstructured":"Poon, LC, Shennan, A, Hyett, JA, Kapur, A, Hadar, E, Divakar, H, et al.. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre\u2010eclampsia: a pragmatic guide for first\u2010trimester screening and prevention. Int J Gynecol Obstet 2019;145:1\u201333. https:\/\/doi.org\/10.1002\/ijgo.12802.","DOI":"10.1002\/ijgo.12892"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_003","unstructured":"American College of Obstetricians and Gynecologists. Task force on hypertension in pregnancy. Hypertension in pregnancy. Report of the American college of obstetricians and gynecologists\u2019 task force on hypertension in pregnancy. Obstet Gynecol 2013;122:1122\u201331."},{"key":"2023040100081895961_j_jpm-2022-0127_ref_004","unstructured":"National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management [Online]; 2019. NICE guideline [NG133] Available from: https:\/\/www.nice.org.uk\/guidance\/ng133 [Accessed Nov 2019]."},{"key":"2023040100081895961_j_jpm-2022-0127_ref_005","doi-asserted-by":"crossref","unstructured":"Zeisler, H, Llurba, E, Chantraine, F, Vatish, M, Staff, AC, Sennstr\u00f6m, M, et al.. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 2016;374:13\u201322. https:\/\/doi.org\/10.1056\/nejmoa1414838.","DOI":"10.1056\/NEJMoa1414838"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_006","doi-asserted-by":"crossref","unstructured":"Levine, RJ, Maynard, SE, Qian, C, Lim, KH, England, LJ, Yu, KF, et al.. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672\u201383. https:\/\/doi.org\/10.1056\/nejmoa031884.","DOI":"10.1056\/NEJMoa031884"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_007","doi-asserted-by":"crossref","unstructured":"Verlohren, S, Herraiz, I, Lapaire, O, Schlembach, D, Zeisler, H, Calda, P, et al.. New gestational phase\u2013specific cutoff values for the use of the soluble fms-like tyrosine kinase-1\/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014;63:346\u201352. https:\/\/doi.org\/10.1161\/hypertensionaha.113.01787.","DOI":"10.1161\/HYPERTENSIONAHA.113.01787"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_008","doi-asserted-by":"crossref","unstructured":"Brown, MA, Magee, LA, Kenny, LC, Karumanchi, SA, McCarthy, FP, Saito, S, et al.. Hypertensive disorders of pregnancy. ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018;72:24\u201343. https:\/\/doi.org\/10.1161\/hypertensionaha.117.10803.","DOI":"10.1161\/HYPERTENSIONAHA.117.10803"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_009","unstructured":"Vaas, P, Rull, K, P\u00f5llumaa, S, Kirss, A, Meigas, D. Estonian Gynaecologists\u00b4 Society. Raseduse j\u00e4lgimise juhend [Guideline for antenatal care]. In Estonian. [Online]; 2011. Available from: https:\/\/www.ens.ee\/ravijuhendid [Accessed 23 June 2019]."},{"key":"2023040100081895961_j_jpm-2022-0127_ref_010","doi-asserted-by":"crossref","unstructured":"Villar, J, Papageorghiou, AT, Pang, R, Ohuma, EO, Ismail, LC, Barros, F. The likeness of fetal growth and new-born size across non-isolated populations in the INTERGROWTH-21st project: the fetal growth longitudinal study and newborn cross-sectional study. Lancet 2014;2:781\u201392. https:\/\/doi.org\/10.1016\/s2213-8587(14)70121-4.","DOI":"10.1016\/S2213-8587(14)70121-4"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_011","doi-asserted-by":"crossref","unstructured":"Cowans, NJ, Alfthan, H, Stenman, UH, Spencer, K. Stability of first trimester placental growth factor in serum and whole blood. Prenat Diagn 2011;31:1193\u20137. https:\/\/doi.org\/10.1002\/pd.2894.","DOI":"10.1002\/pd.2894"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_012","doi-asserted-by":"crossref","unstructured":"Wa Law, L, Sahota, DS, Wai Chan, L, Chen, M, Kin Lau, T, Leung, TY. Effect of long-term storage on placental growth factor and fms-like tyrosine kinase 1 measurements in samples from pregnant women. J Matern Fetal Neonatal Med 2010;23:1475\u201380. https:\/\/doi.org\/10.3109\/14767051003678242.","DOI":"10.3109\/14767051003678242"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_013","doi-asserted-by":"crossref","unstructured":"Stepan, H, Herraiz, I, Schlembach, D, Verlohren, S, Brennecke, S, Chantraine, F, et al.. Implementation of the sFlt-1\/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol 2015;45:241\u20136. https:\/\/doi.org\/10.1002\/uog.14799.","DOI":"10.1002\/uog.14799"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_014","doi-asserted-by":"crossref","unstructured":"Dragan, I, Georgiou, T, Prodan, N, Akolekar, R, Nicolaides, KH. Screening for pre-eclampsia using sFlt-1\/PlGF ratio cut-off of 38 at 30\u201337\u00a0weeks\u2019 gestation. Ultrasound Obstet Gynecol 2017;49:73\u20137. https:\/\/doi.org\/10.1002\/uog.17301.","DOI":"10.1002\/uog.17301"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_015","doi-asserted-by":"crossref","unstructured":"Sovio, U, Gaccioli, F, Cook, E, Hund, M, Charnock-Jones, DS, Smith, GC, et al.. Prediction of preeclampsia using the soluble fms-like tyrosine kinase 1 to placental growth factor ratio. A prospective cohort study of unselected nulliparous women. Hypertension 2017;69:731\u20138. https:\/\/doi.org\/10.1161\/hypertensionaha.116.08620.","DOI":"10.1161\/HYPERTENSIONAHA.116.08620"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_019","doi-asserted-by":"crossref","unstructured":"Dragan, I, Wright, D, Fiolna, M, Leipold, G, Nicolaides, KH. Development of pre-eclampsia within 4\u00a0weeks of sFlt-1\/PlGF ratio>38: comparison of performance at 31\u201334 vs. 35\u201337\u00a0weeks\u2019 gestation. Ultrasound Obstet Gynecol 2017;49:209\u201312. https:\/\/doi.org\/10.1002\/uog.17310.","DOI":"10.1002\/uog.17310"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_020","doi-asserted-by":"crossref","unstructured":"Mitlid-Mork, B, Bowe, S, Gran, JM, Bolstad, N, Berg, JP, Redman, CW, et al.. Maternal placental growth factor and soluble fms-like tyrosine kinase-1 reference ranges in post-term pregnancies: a prospective observational study. PLoS One 2020;15:e0240473. https:\/\/doi.org\/10.1371\/journal.pone.0240473.","DOI":"10.1371\/journal.pone.0240473"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_021","doi-asserted-by":"crossref","unstructured":"Lee, VR, Pilliod, RA, Frias, AE, Rasanen, JP, Shaffer, BL, Caughey, AB. When is the optimal time to deliver late preterm IUGR fetuses with abnormal umbilical artery Dopplers? J Matern Fetal Neonatal Med 2016;29:690\u20135. https:\/\/doi.org\/10.3109\/14767058.2015.1018170.","DOI":"10.3109\/14767058.2015.1018170"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_016","doi-asserted-by":"crossref","unstructured":"Cerdeira, AS, O\u2019Sullivan, J, Ohuma, EO, Harrington, D, Szafranski, P, Black, R, et al.. Randomized interventional study on prediction of preeclampsia\/eclampsia in women with suspected preeclampsia: INSPIRE. Hypertension 2019;74:983\u201390. https:\/\/doi.org\/10.1161\/hypertensionaha.119.12739.","DOI":"10.1161\/HYPERTENSIONAHA.119.12739"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_017","doi-asserted-by":"crossref","unstructured":"Zeisler, H, Llurba, E, Chantraine, FJ, Vatish, M, Staff, AC, Sennstr\u00f6m, et al.. Soluble fms\u2010like tyrosine kinase\u20101 to placental growth factor ratio: ruling out pre\u2010eclampsia for up to 4\u00a0weeks and value of retesting. Ultrasound Obstet Gynecol 2019;53:367\u201375. https:\/\/doi.org\/10.1002\/uog.19178.","DOI":"10.1002\/uog.19178"},{"key":"2023040100081895961_j_jpm-2022-0127_ref_018","doi-asserted-by":"crossref","unstructured":"Dr\u00f6ge, LA, Perschel, FH, St\u00fctz, N, Gafron, A, Frank, L, Busjahn, A, et al.. Prediction of preeclampsia-related adverse outcomes with the sFlt-1 (soluble fms-like tyrosine kinase 1)\/PlGF (placental growth factor)-ratio in the clinical routine: a real-world study. Hypertension 2021;77:461\u201371.","DOI":"10.1161\/HYPERTENSIONAHA.120.15146"}],"container-title":["Journal of Perinatal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2022-0127\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2022-0127\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T14:04:17Z","timestamp":1680357857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpm-2022-0127\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,5,25]]},"published-print":{"date-parts":[[2022,9,27]]}},"alternative-id":["10.1515\/jpm-2022-0127"],"URL":"https:\/\/doi.org\/10.1515\/jpm-2022-0127","relation":{},"ISSN":["0300-5577","1619-3997"],"issn-type":[{"value":"0300-5577","type":"print"},{"value":"1619-3997","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]}}}